🔎 Trials Near Me

Почетна › Беркитов лимфом › Илиноис

Клинички испитувања за Беркитов лимфом во Илиноис

14 студии за Беркитов лимфом бараат учесници на локации во Илиноис.

Градови во Илиноис

Официјален текст на студијата (англиски)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • и уште 4
Се регрутираФаза 2
366 Days – 46 Years · Сите полови · Ажурирано 2.10.2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
  • и уште 7
Се регрутираФаза 3
Возраст од 18 до 39 · Сите полови · Ажурирано 2.10.2026 · NCT03150693

Blinatumomab Consolidation in Real World

  • Northwestern University, Chicago
  • The University of Chicago, Chicago
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • и уште 9
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • Advocate Children's Hospital-Oak Lawn, Oak Lawn
  • и уште 3
Се регрутираФаза 2
365 Days · Сите полови · Ажурирано 25.9.2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • и уште 2
Се регрутираФаза 2
Возраст од 1 до 30 · Сите полови · Ажурирано 1.9.2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • и уште 5
Се регрутираФаза 3
365 Days – 25 Years · Сите полови · Ажурирано 25.8.2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Се регрутираФаза 2
Возраст од 7 до 25 · Сите полови · Ажурирано 19.8.2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, Chicago
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 19.8.2026 · NCT06137118

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  • Research Site, Chicago
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 13.7.2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • University of Chicago Comprehensive Cancer Center, Chicago
Се регрутираФаза 2
Возраст од 18 до 54 · Сите полови · Ажурирано 17.3.2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

  • University of Chicago Comprehensive Cancer Center, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 4.11.2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  • University of Chicago, Chicago
Се регрутираФаза 1/2
Возраст од 15 до 50 · Сите полови · Ажурирано 9.9.2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Се регрутира
Возраст од 18 до 50 · Сите полови · Ажурирано 19.6.2025 · NCT06785324

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.